healthcare News

Sangamo raises $25M at 17% discount, diluting shareholders 15.8%
Healthcare
1mo ago

Sangamo raises $25M at 17% discount, diluting shareholders 15.8%

Strategic funding provides working capital as clinical-stage biotech advances key pipeline programs toward regulatory submissions

Replimune surges 6% on earnings beat, financing relief
Healthcare
1mo ago

Replimune surges 6% on earnings beat, financing relief

Hercules loan amendment extends cash runway to Q1 2027 as April PDUFA date for melanoma therapy confirmed

Merck cuts 2026 outlook by 43% on Gardasil plunge, margin squeeze
Healthcare
1mo ago

Merck cuts 2026 outlook by 43% on Gardasil plunge, margin squeeze

Pharmaceutical giant faces steep earnings decline as vaccine demand collapses in China and pandemic therapies fade

DaVita shares climb 1.7% on earnings beat, strong 2026 outlook
Healthcare
1mo ago

DaVita shares climb 1.7% on earnings beat, strong 2026 outlook

Dialysis provider projects 33% EPS growth and continues aggressive share buybacks

CorMedix authorizes $75M buyback after January stock plunge
Healthcare
1mo ago

CorMedix authorizes $75M buyback after January stock plunge

Biopharmaceutical company launches repurchase program representing 12.3% of market cap, signaling confidence at depressed valuations

Revvity beats earnings forecasts, raises outlook on diagnostics strength
Healthcare
1mo ago

Revvity beats earnings forecasts, raises outlook on diagnostics strength

Healthcare technology company posts $772 million in fourth-quarter revenue and projects FY2026 EPS growth to $5.35-$5.45

AstraZeneca bets $18.5B on obesity drugs with China's CSPC
Healthcare
1mo ago

AstraZeneca bets $18.5B on obesity drugs with China's CSPC

Pharmaceutical giant pays $1.2 billion upfront for once-monthly GLP-1 treatments in race to catch Novo Nordisk and Eli Lilly

Obesity drug shares face pressure as AstraZeneca enters market
Healthcare
1mo ago

Obesity drug shares face pressure as AstraZeneca enters market

AstraZeneca's $4.7B deal with China's CSPC targets once-monthly dosing to challenge LLY/NVO duopoly